Letter by May et al regarding article, "use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation" by Bassiouny et al.

Circulation: Arrhythmia and Electrophysiology

Volumn 6, Issue 4, 2013, Pages

  May, Marc Antoine ^a   Gruel, Yves ^a   Fauchier, Laurent ^a  

^a SERVICE DE DERMATOLOGIE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

DABIGATRAN; HEPARIN; WARFARIN;

ANTICOAGULATION; BLOOD CLOTTING TIME; CATHETER ABLATION; HEART ATRIUM FIBRILLATION; HEART CATHETERIZATION; HUMAN; IN VITRO STUDY; LETTER; PARTIAL THROMBOPLASTIN TIME; PRACTICE GUIDELINE; PRIORITY JOURNAL; PULMONARY VEIN ISOLATION; THROMBOEMBOLISM;

ANTICOAGULANTS; ATRIAL FIBRILLATION; BENZIMIDAZOLES; BETA-ALANINE; FEMALE; HUMANS; MALE; THROMBOEMBOLISM; WARFARIN;

EID: 84884519712     PISSN: 19413149     EISSN: 19413084     Source Type: Journal    
DOI: 10.1161/CIRCEP.113.000515     Document Type: Letter

References (5)

1. Bassiouny M, Saliba W, Rickard J, Shao M, Sey A, Diab M, Martin DO, Hussein A, Khoury M, Abi-Saleh B, Alam S, Sengupta J, Borek PP, Baranowski B, Niebauer M, Callahan T, Varma N, Chung M, Tchou PJ, Kanj M, Dresing T, Lindsay BD, Wazni O. Use of dabigatran for periprocedural anticoagulation in patients undergoing catheter ablation for atrial fibrillation. Circ Arrhythm Electrophysiol. 2013;6: 460-466.
2. Calkins H, Kuck KH, Cappato R, Brugada J, Camm AJ, Chen SA, Crijns HJ, Damiano RJ Jr, Davies DW, DiMarco J, Edgerton J, Ellenbogen K, Ezekowitz MD, Haines DE, Haissaguerre M, Hindricks G, Iesaka Y, Jackman W, Jalife J, Jais P, Kalman J, Keane D, Kim YH, Kirchhof P, Klein G, Kottkamp H, Kumagai K, Lindsay BD, Mansour M, Marchlinski FE, McCarthy PM, Mont JL, Morady F, Nademanee K, Nakagawa H, Natale A, Nattel S, Packer DL, Pappone C, Prystowsky E, Raviele A, Reddy V, Ruskin JN, Shemin RJ, Tsao HM, Wilber D; Heart Rhythm Society Task Force on Catheter and Surgical Ablation of Atrial Fibrillation. 2012 HRS/ EHRA/ECAS expert consensus statement on catheter and surgical ablation of atrial fibrillation: recommendations for patient selection, procedural techniques, patient management and follow-up, definitions, endpoints, and research trial design. Heart Rhythm. 2012;9: 632-696.
3. van Ryn J, Stangier J, Haertter S, Liesenfeld KH, Wienen W, Feuring M, Clemens A. Dabigatran etexilate-a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity. Thromb Haemost. 2010;103: 1116-1127.
4. Lakkireddy D, Reddy YM, Di Biase L, Vanga SR, Santangeli P, Swarup V, Pimentel R, Mansour MC, D'Avila A, Sanchez JE, Burkhardt JD, Chalhoub F, Mohanty P, Coffey J, Shaik N, Monir G, Reddy VY, Ruskin J, Natale A. Feasibility and safety of dabigatran versus warfarin for periprocedural anticoagulation in patients undergoing radiofrequency ablation for atrial fibrillation: results from a multicenter prospective registry. J Am Coll Cardiol. 2012;59: 1168-1174.
5. Winkle RA, Mead RH, Engel G, Kong MH, Patrawala RA. The use of dabigatran immediately after atrial fibrillation ablation. J Cardiovasc Electrophysiol. 2012;23: 264-268.